Streetbeat News

Analyst Ratings

BABA

Morgan Stanley analyst Gary Yu has maintained an Equal-Weight rating on Alibaba Group Holding (BABA) and has also maintained the price target of $85.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:09 pm

NFLX

Barclays analyst Kannan Venkateshwar maintains an Equal-Weight rating on Netflix (NASDAQ:NFLX) and raises the price target from $475 to $550.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:08 pm

TSLA

Morgan Stanley analyst Adam Jonas maintains an Overweight rating on Tesla (TSLA) with a $310 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:08 pm

CBOE

Morgan Stanley analyst Michael Cyprys downgraded Cboe Global Markets (CBOE) from Overweight to Equal-Weight and reduced the price target from $211 to $199.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:05 pm

TRGP

Barclays analyst Christine Cho maintains an Overweight rating on Targa Resources (TRGP) and raises the price target from $116 to $122.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:05 pm

SYF

Barclays analyst Mark Devries maintains an Equal-Weight rating on Synchrony Financial (SYF) and raises the price target from $36 to $37.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:03 pm

GE

TD Cowen analyst Gautam Khanna upgraded GE Aero, a division of General Electric (NYSE:GE), from Hold to Buy and increased the price target from $175 to $180.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:01 pm

ITGR

Integer Holdings (NYSE:ITGR) has received mixed analyst ratings over the past three months, with an average 12-month price target of $129.25, marking a 9.84% increase from the previous target. The company, a manufacturer of medical device components, shows a positive revenue trend with a growth rate of 10.94% as of December 31, 2023, and outperforms industry standards in net margin, ROE, and ROA, despite a market capitalization below industry benchmarks.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 12:01 pm

LPLA

Morgan Stanley analyst Michael Cyprys upgraded LPL Finl Hldgs (NASDAQ:LPLA) from Equal-Weight to Overweight and increased the price target from $254 to $315.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:01 pm

TSHA

Taysha Gene Therapies (NASDAQ:TSHA) has received mixed reviews from 7 financial analysts over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target for TSHA has been raised to $6.71, indicating a 34.2% increase from the previous target of $5.00. Analysts from firms including Piper Sandler, Canaccord Genuity, Chardan Capital, JMP Securities, Cantor Fitzgerald, and Needham have provided updates, with actions ranging from maintaining to raising their price targets. Taysha Gene Therapies, a gene therapy company focused on CNS diseases, has shown notable financial performance with a revenue growth of 44.04%, an impressive net margin of 1324.67%, and a high ROE of 369.76%, despite a high debt-to-equity ratio of 0.82.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 12:01 pm